Ulcerative Colitis: key endpoint results by drug

The key endpoints of Ulcerative Colitis trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Ulcerative Colitis page.

Clinical remission (induction)

Clinical remission (induction) in Ulcerative Colitis: 15 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
adalimumab10%11.5%−1.5160 mg/80 mg · wk 8 · n 90NCT00853099 Phase 3, primary
afimkibart23.9%11.6%+12.3450 mg · wk 14 · n 88NCT04090411 Phase 2, primary
duvakitug47.8%20.5%+27.3900 mg · wk 14 · n 46NCT05499130 Phase 2b, primary
etrasimod27%7.4%+19.62 mg · wk 12 · n 274NCT03945188 Phase 3, primary
golimumab17.9%6.4%+11.5400 mg -> 200 mg · wk 6 · n 257NCT00487539 Phase 2/3, secondary
guselkumab22.6%7.9%+14.7200 mg IV · wk 12 · n 421NCT04033445 Phase 3, primary
mirikizumab24.2%13.3%+10.9300 mg IV Q4W · wk 12 · n 868NCT03518086 Phase 3, primary
obefazimod17.5%12.5%+550 mg · wk 8 · n 63NCT03760003 Phase 2, secondary
ozanimod18.4%6%+12.4wk 10 · n 429NCT02435992 Phase 3, primary
risankizumab20.3%6.2%+14.11200 mg IV · wk 12 · n 650NCT03398148 Phase 2/3, primary
tofacitinib16.6%3.6%+1310 mg BID · wk 8 · n 429NCT01458951 Phase 3, primary
tulisokibart26.5%1.5%+25wk 12 · n 68NCT04996797 Phase 2, primary
upadacitinib26.1%4.8%+21.345 mg · wk 8 · n 319NCT02819635 Phase 2/3, primary
ustekinumab15.6%5.3%+10.3130 mg IV · wk 8 · n 320NCT02407236 Phase 3, primary
vedolizumab18.3%12.2%+6.1300 mg · wk 10 · n 164NCT02039505 Phase 3, secondary

Drugs checked with no result here: 8 trial running, 65 not reported, 4 not posted.

Clinical remission (maintenance)

Clinical remission (maintenance) in Ulcerative Colitis: 9 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
adalimumab20%7.3%+12.7160 mg/80 mg · wk 52 · n 90NCT00853099 Phase 3, primary
etrasimod32.1%6.7%+25.42 mg · wk 52 · n 274NCT03945188 Phase 3, primary
guselkumab50%18.9%+31.1200 mg SC q4w · wk 44 · n 190NCT04033445 Phase 3, primary
mirikizumab49.9%25.1%+24.8200 mg SC · wk 40 · n 365NCT03524092 Phase 3, primary
ozanimod37%18.5%+18.5wk 52 · n 230NCT02435992 Phase 3, primary
tofacitinib40.6%11.1%+29.510 mg BID · wk 52 · n 197NCT01458574 Phase 3, primary
upadacitinib51.7%12.1%+39.630 mg · wk 52 · n 154NCT02819635 Phase 2/3, primary
ustekinumab43.8%24%+19.890 mg SC every 8 weeks (q8w) · wk 44 · n 176NCT02407236 Phase 3, primary
vedolizumab46.2%14.3%+31.9108 mg SC · wk 52 · n 106NCT02611830 Phase 3, primary

Drugs checked with no result here: 14 trial running, 65 not reported, 4 not posted.

Clinical response (induction)

Clinical response (induction) in Ulcerative Colitis: 15 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
adalimumab50%35.4%+14.6160 mg/80 mg · wk 8 · n 90NCT00853099 Phase 3, secondary
duvakitug69.6%52.3%+17.3900 mg · wk 14 · n 46NCT05499130 Phase 2b, secondary
etrasimod62.4%34.1%+28.32 mg · wk 12 · n 274NCT03945188 Phase 3, secondary
golimumab54.9%30.3%+24.6400 mg -> 200 mg · wk 6 · n 257NCT00487539 Phase 2/3, primary
guselkumab61.4%27.6%+33.8200 mg IV · wk 12 · n 101NCT04033445 Phase 3, primary
mirikizumab63.5%42.2%+21.3300 mg IV Q4W · wk 12 · n 868NCT03518086 Phase 3, secondary
obefazimod58.7%34.4%+24.350 mg · wk 8 · n 63NCT03760003 Phase 2, secondary
ozanimod47.8%25.9%+21.9wk 10 · n 429NCT02435992 Phase 3, secondary
risankizumab64.3%35.7%+28.61200 mg IV · wk 12 · n 650NCT03398148 Phase 2/3, secondary
spesolimab0.3%0.2%±01200 mg q4w · wk 12 · n 28NCT03482635 Phase 2/3, secondary
tofacitinib55%28.6%+26.410 mg BID · wk 8 · n 429NCT01458951 Phase 3, secondary
tulisokibart66.2%22.4%+43.8wk 12 · n 68NCT04996797 Phase 2, secondary
upadacitinib72.6%27.3%+45.345 mg · wk 8 · n 319NCT02819635 Phase 2/3, secondary
ustekinumab51.3%31.3%+20130 mg IV · wk 8 · n 320NCT02407236 Phase 3, secondary
vedolizumab39.6%32.9%+6.7300 mg · wk 10 · n 164NCT02039505 Phase 3, primary

Drugs checked with no result here: 9 trial running, 64 not reported, 4 not posted.

Endoscopic improvement (induction)

Endoscopic improvement (induction) in Ulcerative Colitis: 10 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
adalimumab44.4%30.2%+14.2160 mg/80 mg · wk 8 · n 90NCT00853099 Phase 3, secondary
afimkibart40.9%18.6%+22.3450 mg · n 88NCT04090411 Phase 2, secondary
etrasimod35%14.1%+20.92 mg · wk 12 · n 274NCT03945188 Phase 3, secondary
mirikizumab13.1%6.3%+6.8600 mg IV Q4W · wk 12 · n 61NCT02589665 Phase 2, secondary
ozanimod27.3%11.6%+15.7wk 10 · n 429NCT02435992 Phase 3, secondary
risankizumab36.5%12.1%+24.41200 mg IV · wk 12 · n 650NCT03398148 Phase 2/3, secondary
tofacitinib28.4%11.6%+16.810 mg BID · wk 8 · n 429NCT01458951 Phase 3, secondary
tulisokibart36.8%6%+30.8wk 12 · n 68NCT04996797 Phase 2, secondary
upadacitinib36.3%7.4%+28.945 mg · wk 8 · n 319NCT02819635 Phase 2/3, secondary
vedolizumab36.6%30.5%+6.1300 mg · wk 10 · n 164NCT02039505 Phase 3, secondary

Drugs checked with no result here: 13 trial running, 65 not reported, 4 not posted.

Corticosteroid-free remission (maintenance)

Corticosteroid-free remission (maintenance) in Ulcerative Colitis: 6 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
adalimumab13.3%5.7%+7.6160/80/40 · wk 52 · n 150NCT00408629 Phase 3, secondary
etrasimod32.1%6.7%+25.42 mg · wk 52 · n 274NCT03945188 Phase 3, secondary
golimumab23.2%18.4%+4.8100 mg · wk 54 · n 82NCT00488631 Phase 3, secondary
ozanimod31.7%16.7%+15wk 52 · n 230NCT02435992 Phase 3, secondary
ustekinumab42%23.4%+18.690 mg SC every 8 weeks (q8w) · wk 44 · n 176NCT02407236 Phase 3, secondary
vedolizumab28.9%8.3%+20.6108 mg SC · wk 52 · n 45NCT02611830 Phase 3, secondary

Drugs checked with no result here: 16 trial running, 5 not posted, 65 not reported.

  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 92 approved or late-stage drugs with a featured trial in Ulcerative Colitis were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.